arrow
M

Mary Frances McMullin

Belfast Health and Social Care Trust
H指数:55
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom

英国大型多中心队列分析揭示加速期和原始细胞期骨髓增殖性肿瘤的治疗模式与结局

2026-05-030
OAAI
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE)

初步安全性和有效性:Navitoclax联合Ruxolitinib在Janus Kinase抑制剂初治的骨髓纤维化患者中的研究(多中心、开放标签、II期研究REFINE)

2026-03-170
OAAI
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera

治疗对青少年和年轻成人真性红细胞增多症和原发性血小板增多症的影响

LEUKEMIA
IF13.4
2025-03-120
OA
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies
2024-05-014
PRE
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis
2023-11-253
OAAI
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
2023-11-013
OAAI
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
LEUKEMIA
IF13.4
2023-08-0920
OAAI
Characterization of genetic variants in the EGLN1/PHD2 gene identified in a European collection of patients with erythrocytosis
2023-06-155
OAAI
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation
2023-06-055
OAAI
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
2022-09-0620
OAAI
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program
2021-03-0632
OAAI
Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm
LEUKEMIA
IF13.4
2021-02-1210
OAAI
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
2021-01-1139
OA
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
LEUKEMIA
IF13.4
2020-08-078
OAAI